CompanyGraph
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 4.36: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.68%
Annual Rate
CNY 0.20Paid annual
Payout Ratio
926.4%High
Payback Period
59.6 yr
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
7.46BCNY1.11B · vs all stocks (USD)
Trailing P/E
313.75xRevenue (TTM)
1.03BCNY152.92M · vs all stocks (USD)
Profit Margin
2.19%Beta
0.5060xvs all stocks
52-Week Change
-30.41%vs all stocks
Market Capitalization
7.46BCNY1.11B · vs all stocks (USD)
Enterprise Value
5.75BCNY854.38M · vs all stocks (USD)
Trailing P/E
313.75xPrice to Sales (TTM)
7.64xPrice to Book (MRQ)
2.07xEnterprise to Revenue
5.59xEnterprise to EBITDA
47.47xGross Margin
79.18%Profit Margin
2.19%Operating Margin
15.15%Return on Assets (TTM)
0.36%Return on Equity (TTM)
0.46%Revenue (TTM)
1.03BCNY152.92M · vs all stocks (USD)
Revenue per Share (TTM)
1.66CNYUpdated Aug 21, 2026Quarterly Revenue Growth
12.60%Gross Profit (TTM)
802.40MCNY119.32M · vs all stocks (USD)
EBITDA (TTM)
121.55MCNY18.07M · vs all stocks (USD)
Net Income (TTM)
22.53MCNY3.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
11.00%Operating Cash Flow (TTM)
108.12MCNY16.08M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-44.99MCNY-6.69M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
1.68%vs all stocks
Payout Ratio
926.39%Minority Interest (Equity)
-11.25MCNYFY2025 · Dec 31, 2025Revenue
998.14MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
203.60MCNYFY2025 · Dec 31, 2025Gross Profit
794.55MCNYFY2025 · Dec 31, 2025Operating Income
59.51MCNY8.85M · vs all stocks (USD)
Pre-tax Income
-64.31MCNYFY2025 · Dec 31, 2025Income Tax Expense
-33.77MCNYFY2025 · Dec 31, 2025Net Income
-30.55MCNYFY2025 · Dec 31, 2025EBIT
-54.53MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
211.86MCNYFY2025 · Dec 31, 2025Research & Development
302.71MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
346.56MCNYFY2025 · Dec 31, 2025Other Operating Expenses
9.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
53.05MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
9.78MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0405CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0405CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
615.72MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
615.72MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-30.55MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.59MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-212.93MCNYFY2025 · Dec 31, 2025Free Cash Flow
-317.91MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.38BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-30.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.13MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-41.96MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-145.55MCNYFY2025 · Dec 31, 2025Capital Expenditures
-104.97MCNYFY2025 · Dec 31, 2025Purchase of Investments
-450.82MCNYFY2025 · Dec 31, 2025Sale of Investments
687.18MCNYFY2025 · Dec 31, 2025Other Investing Activity
-600.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
130.79MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
493.15MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-385.10MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-199.07MCNYFY2025 · Dec 31, 2025Other Financing Charges
190.97MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
99.95MCNYFY2025 · Dec 31, 2025Shares Outstanding
626.93MSharesUpdated Aug 21, 2026Float Shares
275.70MSharesUpdated Aug 21, 2026% Held by Insiders
50.74%vs all stocks
% Held by Institutions
10.48%vs all stocks
Total Cash (MRQ)
2.76BCNY410.76M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.43CNYUpdated Aug 21, 2026Total Debt (MRQ)
690.61MCNY102.70M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1832xCurrent Ratio (MRQ)
2.61xBook Value per Share (MRQ)
6.06CNYUpdated Aug 21, 2026Total Assets
5.02BCNY746.45M · vs all stocks (USD)
Total Current Assets
3.17BCNYFY2025 · Dec 31, 2025Total Liabilities
1.27BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.85BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
91.66MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.18BCNYFY2025 · Dec 31, 2025Cash
2.38BCNYFY2025 · Dec 31, 2025Cash Equivalents
25.76MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.40BCNYFY2025 · Dec 31, 2025Other Short-term Investments
278.43MCNYFY2025 · Dec 31, 2025Accounts Receivable
92.33MCNYFY2025 · Dec 31, 2025Inventory
263.75MCNYFY2025 · Dec 31, 2025Accounts Payable
146.14MCNYFY2025 · Dec 31, 2025Short-term Debt
603.23MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.42MCNYFY2025 · Dec 31, 2025Common Stock (Book)
423.60MCNYFY2025 · Dec 31, 2025Retained Earnings
729.58MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.75BCNY557.21M · vs all stocks (USD)
Treasury Stock
30.02MCNYFY2025 · Dec 31, 202552-Week Low
9.61CNYUpdated Aug 21, 202652-Week High
19.11CNYUpdated Aug 21, 202652-Week Change
-30.41%vs all stocks
Beta
0.5060xvs all stocks
50-Day MA
11.51CNYUpdated Aug 21, 2026200-Day MA
12.65CNYUpdated Aug 21, 2026Avg 10-Day Volume
14.81MSharesUpdated Aug 21, 2026Avg 30-Day Volume
16.42MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.0400CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.13Receivables vs revenue divergence: 2.56
High gross margins eroded by operating costsNotable
Gross Margin: 0.79Profit Margin: 0.02
Financial Health
Altman Z-Score 4.36: safe zoneNotable
Altman Z-Score: 4.36
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Inventiva S.A.
Tier 1ProductionApproval-Gated PipelineRule
Inkon Life Tech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EyePoint Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Frontier Biotechnologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Star Lake Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Sun-Novo Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Neuromeka Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated